Welcome to our dedicated page for Goodrx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on Goodrx Holdings stock.
GoodRx Holdings, Inc. (NASDAQ: GDRX) is widely described as the leading platform for medication savings in the U.S., and its news flow reflects that role at the intersection of digital healthcare, pharmacy, and pharmaceutical manufacturers. Company announcements highlight new partnerships, product launches, and financial updates that shape how consumers, pharmacies, and manufacturers approach prescription affordability.
News about GoodRx often covers collaborations with major healthcare players. Examples include the RxSmartSaver program powered by GoodRx at national and regional retail pharmacies, which brings brand medication savings directly to the pharmacy counter, and an exclusive partnership with Surescripts that integrates GoodRx discounted cash prices into Script Corner, a patient experience product focused on prescription price transparency.
GoodRx also issues press releases on new consumer offerings and subscriptions. Recent updates describe GoodRx for Weight Loss, a telemedicine subscription for GLP-1 weight management treatment, and GoodRx for Hair Loss, a subscription program for men that combines virtual consultations, prescriptions for oral finasteride or oral minoxidil when appropriate, and discreet home delivery. Additional news highlights defined cash prices for medications such as Repatha, Ozempic, Wegovy, and the Wegovy pill at tens of thousands of pharmacies nationwide via GoodRx.
Investors and observers can also find earnings-related news, including quarterly financial results, guidance commentary, and participation in healthcare conferences. Together, these updates provide insight into GoodRx’s strategy across prescription transactions, subscriptions, pharma manufacturer solutions, and telehealth. For anyone tracking GDRX, this news page offers a focused view of how the company is evolving its platform, expanding partnerships, and addressing medication affordability across the U.S. healthcare system.
GoodRx Holdings, Inc. (NASDAQ: GDRX) has appointed Scott Wagner, former CEO of GoDaddy, as its Interim CEO, effective April 25, 2023. Co-founders Doug Hirsch and Trevor Bezdek will transition to roles as Chief Mission Officer and Chairman, respectively. Wagner brings over 25 years of experience and aims to enhance product innovation and customer base growth. With his leadership, GoodRx aims to improve healthcare accessibility and affordability, having helped Americans save over $55 billion on medications. Hirsch will continue to focus on operationalizing the company's mission, while Bezdek will guide healthcare strategy and innovation. An update for investors is anticipated during the earnings call on May 10.
GoodRx Holdings, Inc. (GDRX) will release its Q1 2023 financial results before U.S. markets open on May 10, 2023. A conference call is scheduled for 5:00 a.m. Pacific Time to discuss the results and business outlook. GoodRx, a leading digital healthcare platform, provides consumers with access to lower prices for medications and telehealth consultations. Since its inception in 2011, GoodRx has helped individuals save over $55 billion on healthcare costs. The earnings call will be accessible online, and an archived version will be available for 30 days post-call.
GoodRx Holdings, Inc. (Nasdaq: GDRX) reported its fourth quarter and full-year 2022 financial results, exceeding previous guidance. Q4 2022 revenue was $184.1 million, a 14% decline year-over-year, with a net loss of $2.01 million. Adjusted net income for Q4 stood at $27.4 million. Annual revenue was $766.6 million with a net loss of $32.81 million. Prescription transactions revenue fell 19% due to an 8% drop in Monthly Active Consumers and continued grocer-related issues, estimated to impact revenue by $40-$50 million. Future guidance for Q1 2023 projects revenue of $181-$183 million, reflecting ongoing challenges.
GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, will present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7, 2023, at 6:50 a.m. Pacific Time (9:50 a.m. Eastern Time). A live webcast of the presentation can be accessed through the Company’s investor relations website at https://investors.goodrx.com/, with an archived recording to be available for 30 days afterward. GoodRx has been committed to making healthcare affordable, saving consumers over $45 billion since 2011, and remains one of the most downloaded medical apps in the past decade.
GoodRx Holdings Inc. (NASDAQ: GDRX) will report its fourth quarter and full year 2022 financial results on February 28, 2023, after U.S. markets close. A conference call is scheduled for 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide insights into the company’s future outlook. Investors can pre-register for the call and access a live webcast through GoodRx's investor relations website. Since 2011, GoodRx has saved consumers over $45 billion, offering affordable medication prices and telehealth services.
GoodRx Holdings, Inc. (Nasdaq: GDRX), a top digital healthcare platform, is set to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 11, 2023, at 3:45 p.m. PT. A live webcast of this presentation will be available on the Company's Investor Relations website and will be archived for 30 days. GoodRx has saved consumers over $45 billion since its inception in 2011, providing affordable healthcare solutions to Americans.
GoodRx Holdings, Inc. (GDRX) has reported its third-quarter 2022 financial results, achieving total revenue of $187.3 million, which surpassed previous guidance despite a 4% year-over-year decline. The net loss was $41.7 million, reflecting a challenging environment, particularly from the grocer issue affecting prescription transactions revenue, which decreased 16% to $131.2 million. However, subscription revenue grew by 63% to $26.5 million. Adjusted EBITDA was reported at $52.0 million, a decrease from the prior year, with management anticipating fourth-quarter revenue guidance of $175-$180 million, factoring continued challenges.
GoodRx (NASDAQ: GDRX) released a report indicating that expanding pharmacist prescribing authority significantly enhances access to critical medications, especially for PrEP (HIV prevention pill). The report highlights an increase in PrEP fills by 24% after one year and 110% after two years in states that allow pharmacists to prescribe. Over 37 million Americans reside in under-resourced areas where pharmacist authority could enhance healthcare access. GoodRx emphasizes that improved access leads to better medication adherence, benefiting both patients and healthcare providers.
GoodRx Holdings, Inc. (Nasdaq: GDRX), a digital healthcare platform, will present at two upcoming investor conferences. The first is the Credit Suisse 31st Annual Healthcare Conference on November 10 in Rancho Palos Verdes, CA, at 9:50 a.m. Pacific Time. The second is the Wells Fargo 6th Annual TMT Summit on December 1 in Las Vegas, NV, at 8:40 a.m. Pacific Time. Live webcasts and archived recordings will be available on the Company's Investor Relations website. GoodRx has saved consumers over $40 billion since 2011 and is among the most downloaded medical apps in the past decade.
GoodRx has launched Provider Mode, a dedicated platform for healthcare providers aimed at reducing administrative workload while facilitating patient access to medications. Since June 2021, over 850,000 prescribers have utilized GoodRx for medication pricing and discounts. With a 90% net promoter score among providers, the tool offers features like cost comparison, a dashboard for easy access to resources, and savings programs. Additionally, partnerships with companies like Biogen enhance its offerings to streamline processes for specialty therapies.